Rawan Al-Karaki1, Areeg Awadallah1, Mohammad Saleh1, Maha Nasr2*
1. Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Mutah University, Jordan 2. Department of Pharmaceutics and Industrial pharmacy , Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
Keywords: Oleuropein, nanocapsules, colon cancer, HCT-116 cells.

Nanotechnology has provided substantial contribution in the field of nutraceuticals’ delivery. In the current work, a novel nanocapsular system loading the nutraceutical oleuropein was prepared and characterized, then further tested for its efficacy against colon cancer cells. Oleuropein nanocapsular formulation was prepared by the phase inversion method. Oleuropein nanocapsules were characterized for their particle size, zeta potential, polydispersity index, morphology, in vitro drug release, stability and anticancer activity on HCT-116 colon cancer cells. Oleuropein nanocapsules were successfully prepared with a particle size of 151 nm, polydispersity index of 0.286 and an overall neutral charge. Moreover, it was able to sustain the release of drug for 24 hours with a cumulative percent released of 100%, compared to oleuropein control which displayed 100% release after only 2 hours. Transmission electron microscopic examination of the nanocapsules displayed their small particle size and revealed their spherical morphology in the form of core and coat. The prepared nanocapsular formulation was stable, with no significant changes in particle size, polydispersity or charge observed upon storage. Interestingly, the oleuropein nanocapsular formulation was 28 times more cytotoxic than oleuropein alone on HCT-116 colon cancer cells. Therefore, it can be delineated that nanocapsules act as promising delivery carrier for oleuropein, which is worthy of further experimentation in vivo to determine its bioavailability.

Article Information

Identifiers and Pagination:
First Page:1
Last Page:8
Publisher Id:JAppPharm (2019 ). 11. 1-8
Article History:
Received:March 14, 2019
Accepted:May 10, 2019
Collection year:2019
First Published:May 15, 2019

© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
Editor in Chief
Prof. Dr. Cornelia M. Keck (Philipps-Universität Marburg)
Marburg, Germany


Welcome to the research group of Prof. Dr. Cornelia M. Keck in Marburg. Cornelia M. Keck is a pharmacist and obtained her PhD in 2006 from the Freie Universität (FU) in Berlin. In 2009 she was appointed as Adjunct Professor for Pharmaceutical and Nutritional Nanotechnology at the University Putra Malaysia (UPM) and in 2011 she obtained her Venia legendi (Habilitation) at the Freie Universität Berlin and was appointed as a Professor for Pharmacology and Pharmaceutics at the University of Applied Sciences Kaiserslautern. Since 2016 she is Professor of Pharmaceutics and Biopharmaceutics at the Philipps-Universität Marburg. Her field of research is the development and characterization of innovative nanocarriers for improved delivery of poorly soluble actives for healthcare and cosmetics. Prof. Keck is executive board member of the German Association of Nanotechnology (Deutscher Verband Nanotechnologie), Vize-chairman of the unit „Dermocosmetics“ at the German Society of Dermopharmacy, active member in many pharmaceutical societies and member of the BfR Committee for Cosmetics at the Federal Institute for Risk Assessment (BfR).

Journal Highlights
Abbreviation: J App Pharm
Frequency: Annual 
Current Volume: 9 (2017)
Next scheduled volume: December, 2018 (Volume 10)
Back volumes: 1-9
Starting year: 2009
Nature: Online 
Submission: Online  
Language: English

Subject & Scope
  • Pharmaceutics
  • Physical Pharmacy 
  • Dosage Forms Science 
  • Pharmaceutical Microbiology & Immunology 
  • Industrial Pharmacy 
  • Bio-Pharmaceutics 
  • Pharmaceutical Chemistry 
  • Pharmaceutical Instrumentation 
  • Medicinal Chemistry 
  • Pharmacognosy 
  • Physiology &Histology 
  • Anatomy & Pathology 
  • Pharmacology & Therapeutics 
  • Pharmacy Practice 
  • Pharmaceutical Mathematics   
  • Biostatistics 
  • Dispensing 
  • Community Social & Administrative Pharmacy 
  • Hospital Pharmacy 
  • Clinical Pharmacy 
  • Pharmaceutical Quality Management 
  • Forensic Pharmacy 
  • Pharmaceutical Technology 
  • Pharmaceutical Management & Marketing

Consortium Publisher is an online publisher that enjoys global presence with International Journals

Follow Us

©2009 - 2019 Consortium Publisher Canada

Contact Info

6252 Lisgar Dr Mississauga Ontario L5N7V2 Canada
+1 (647) 526-0885